T1	Participants 282 331	patients with progressive multiple sclerosis (MS)
T2	Participants 913 948	Eighty patients with progressive MS
T3	Participants 968 1084	60 will have secondary progressive disease (SPMS) but a subset (n = 20) will have primary progressive disease (PPMS)
T4	Participants 2306 2317	MS patients
